Brentuximab vedotin improves survival of pediatric patients with classical Hodgkin’s lymphoma:

Brentuximab vedotin improves survival of pediatric patients with classical Hodgkin’s lymphoma
Hodgkin’s lymphoma is the most common malignancy in the age group of 15-19 years and accounts for 7% of all pediatric malignancies.

Brentuximab vedotin has been recently approved by FDA to treat high-risk classical Hodgkin’s lymphoma (cHL) in pediatric patients. The addition of brentuximab to the standard chemotherapy regimen, which includes doxorubicin (A), vincristine (V), etoposide (E), prednisone (P), and cyclophosphamide (C), has shown improved response and better survival rates

Mechanism of action:

Brentuximab vedotin is an antibody-drug conjugate, formed by linking the chimeric anti-CD30 antibody to the antimitotic agent
MMAE (monomethyl auristatin E). It binds to CD30+ Reed-Sternberg cells and induces cell-cycle arrest and apoptosis.

Dosage:

IV brentuximab 1.8 mg/kg (maximum dose 180 mg) in combination with AVEPC every 3 weeks for a maximum of 5 doses in children >or equal to 2 years of age.

Side effects:

Febrile neutropenia, anemia, thrombocytopenia, stomatitis, infections, peripheral neuropathy.

Contraindication:

Simultaneous use of bleomycin with brentuximab can result in pulmonary toxicity.

Reference :  https://www.fda.gov/drugs/resources-information-approved -drugs/fda-approves-brentuximab-vedotin-combination -chemotherapy-pediatric-patients-classical-hodgkin

Visit our Website : www.medicozcommunity.com

How to Crack NEET PG ?